Brenus Pharma
Benoît Pinteur (Chief Scientific Officer, PharmD) brings 25 years of experience in the pharma industry with roles at Shering-Plough and Roche, mainly in pharmaceutical development.
From previous collaboration with international teams on autologous cancer immunotherapy, he decided to create Brenus Pharma to address previous limitations of cancer vaccines.
Benoit was formerly the CEO of BioElpida, a CDMO where he developed expertise in ATMP and GMP manufacturing with a special focus on immunotherapies, cell therapies and vaccines.
Brenus Pharma
Brenus Pharma is an allogeneic platform to generate immune therapy ambitioning to harness patient immune system & prevent cancer resistance.